Diagnostic BioSystems, a Pleasanton, CA-based developer of immunohistochemistry (IHC) solutions in the life science research and anatomic pathology markets, completed a growth capital financing with BroadOak Capital Partners, a life sciences focused merchant bank.
The amount of the transaction was not disclosed.
The company intends to use the proceeds for the expansion into its new facility as well as the further development of sales channels and strategic partnerships in the U.S. In addition, it will enable continued development of novel kits and reagents to add to its portfolio of over 1600 IHC products available worldwide.
Led by Bipin Gutpa Ph.D, CEO, Diagnostic BioSystems is a life sciences company developing and marketing immunohistochemistry kits and reagents for the anatomic pathology and histology markets. Since inception in 1994, the company combines kits, antibodies, instrumentation and novel chromogens to provide a complete suite of IHC products for clinical and research use.
It is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations. The DBS manufacturing site is based in Pleasanton, CA as a CDPH licensed Medical Device Manufacturing facility.